In a report released on January 7, Luca Issi from RBC Capital maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...

Norovirus, often erroneously called the "stomach flu," sickens an estimated 21 million Americans and 685 million people ...

Despite millions of cases of norovirus in the U.S. each year—and a current surge in outbreaks—there is still no vaccine for ...

The potential payout relates to an earlier deal over tax evasion by U.S. clients of Credit Suisse, the rival Swiss bank that UBS acquired in 2023. Seven & i reported a drop in quarterly net profit but ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

The biotech’s efforts to bring its vaccines to the country mean navigating political pushback in the U.S. and the risk of ...

Young biotech Dropshot Therapeutics has hooked in Etherna Immunotherapies with an RNA pact that could net up to $950 million.

The number of layoffs in the U.S. pharmaceutical industry exceeded 14,000 last year, a 9% increase from 2023 ...

Moderna stock was on track to see a weekly gain of 10% as of Wednesday following the first reported bird flu death in the US.

The stock's fall snapped a five-day winning streak.

The biotech group struggled as a whole in 2024, but analysts say the innovation that has always supported the biotech ...